研究单位：[1]BeiGene[2]Sichuan Cancer Hospital Chengdu,Sichuan,China,610042[3]The Second Xiangya Hospital central South University Changsha,Hunan,China,410011[4]The First People's Hospital of Chenzhou Chenzhou,Hunan,China,430407[5]The Second Hospital,University of South China Hengyang,Hunan,China,430407[6]Nanjing First Hospital Nanjing,Jiangsu,China,210009[7]Zhongda Hospital Southeast University Nanjing,Jiangsu,China,210009[8]The Second Affiliated Hospital of Soochow University Suzhou,Jiangsu,China,215000[9]The First Affiliated Hospital of Soochow University Suzhou,Jiangsu,China[10]The Affiliated Hospital of Xuzhou Medical University Xuzhou,Jiangsu,China,221000
研究目的：
The purpose of this study is to evaluate the efficacy and safety of tislelizumab in combination with sitravatinib compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have disease progression following platinum-based chemotherapy and anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) antibody,with the anti-PD-(L)1 antibody administered in combination with or following platinum-based chemotherapy.
